<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910518</url>
  </required_header>
  <id_info>
    <org_study_id>BEQ13941</org_study_id>
    <secondary_id>2016-001498-34</secondary_id>
    <secondary_id>U1111-1183-8636</secondary_id>
    <nct_id>NCT02910518</nct_id>
  </id_info>
  <brief_title>A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-blind, Single-dose, 2-Treatment, 2-Period, 2-Sequence Crossover Bioequivalence Study Comparing Two Formulations of Insulin Glulisine (Insulin Glulisine 300 Units/mL Versus Insulin Glulisine 100 Units/mL Marketed as Apidra® 100 Units/mL) Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test
      formulation and insulin glulisine 100 Units/mL reference formulation after a single
      subcutaneous (SC) dose.

      Secondary Objectives:

        -  To assess the pharmacodynamic (PD) profiles and further pharmacokinetic (PK)
           characteristics of insulin glulisine U300 in comparison to insulin glulisine U100 after
           a single SC dose.

        -  To assess safety and tolerability of the test and the reference formulation of insulin
           glulisine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per patient will be 18 to 62 days and will consist of a 4 to 28 days of
      screening period, a treatment period of 2 days, a washout between dosing occasions of 5-18
      days, and follow up visit 7-14 days after last dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Actual">May 3, 2017</completion_date>
  <primary_completion_date type="Actual">May 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of PK parameter: maximum observed insulin concentration</measure>
    <time_frame>10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PK parameter: area under the concentration time curve</measure>
    <time_frame>10 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: time to reach Cmax (INS-tmax)</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: terminal half-life (INS-t1/2z)</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 10 hours (GIR-AUC0-10)</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: maximum smoothed body weight standardized GIR (GIRmax)</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: time to GIRmax (GIR-tmax)</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of blood glucose control under clamp conditions - time</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment emergent adverse events</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine (U300)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <other_name>HMR1964 (U300)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <other_name>Apidra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: intravenous/subcutaneous</description>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <other_name>NovoRapid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <other_name>Insuman® Basal Solostar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Pharmaceutical form: Powder and solvent for solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <other_name>GlucaGen® HypoKit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: intravenous</description>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <other_name>Glucose 20%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: intravenous</description>
    <arm_group_label>Insulin glulisine - Reference formulation</arm_group_label>
    <arm_group_label>Insulin glulisine (U300) - Test formulation</arm_group_label>
    <other_name>Heparin-Natrium-5000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Male or female subjects with type 1 diabetes mellitus (T1DM) for more than 1 year.

          -  Total insulin dose of &lt;1.2 U/kg/day.

          -  Fasting negative serum C-peptide (&lt;0.30 nmol/L).

          -  Glycohemoglobin at screening (HbA1c) ≤9%.

          -  Subjects with anti-insulin antibody titer at screening ≤30.0 kU/L.

          -  Stable insulin regimen for at least 2 months prior to study.

          -  Normal findings in medical history and physical examination (cardiovascular system,
             chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and
             musculoskeletal system), vital signs, electrocardiogram (ECG), and safety laboratory.

        Exclusion criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic (apart from T1DM), hematological,
             neurological, psychiatric, systemic (affecting the body as a whole), ocular,
             gynecologic (if female), or infectious disease; any acute infectious disease or signs
             of acute illness or any history or presence of heparin induced thrombocytopenia Type
             II (HIT-type II).

          -  Severe hypoglycemia resulting in coma/seizures or requiring assistance of another
             person, and/or hospitalization for diabetic ketoacidosis in the last 6 months before
             screening visit.

          -  Frequent severe headaches and/or migraine, recurrent nausea and/or vomiting (more than
             twice a month).

          -  Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic
             postural hypotension defined by a decrease in systolic blood pressure equal to or
             greater than 20 mmHg within three minutes when changing from the supine to the
             standing position.

          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician.

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol.

          -  Any medication (including medicine containing St John's Wort) within 14 days before
             inclusion (for systemic glucocorticoids within 3 months) or within 5 times the
             elimination half-life or PD half-life of the medication, with the exception of
             insulin, stable treatment (at least 2 months) with thyroid hormones, lipid-lowering
             and antihypertensive drugs and if female with the exception of hormonal contraception
             or menopausal hormone replacement therapy.

          -  Positive reaction to any of the following tests: hepatitis B surface (HBs Ag) antigen,
             anti hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and
             2 antibodies (anti-HIV1 and anti HIV2 Ab).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

